Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZuraGard is a topical preoperative skin preparation consisting of a 70% v/v isopropyl alcohol solution formulated with excipients including citric acid, methylene blue, methylparaben, purified water, and trolamine, and supplied in single-use sterile applicators in multiple fill sizes for small and large surgical fields.[1][2] It acts as a rapid, broad-spectrum antiseptic that reduces bacterial counts on intact skin prior to surgery, providing an alcohol-only alternative for patients who cannot receive chlorhexidine- or iodine-containing products, and was developed and approved via an NDA by Zurex Pharma using the 505(b)(2) pathway with ChloraPrep as the reference product.[1][5][7] Clinical studies demonstrated non-inferiority to chlorhexidine/isopropyl alcohol combinations for log10 reductions in skin flora and acceptable local tolerability, with labeling emphasizing external use, flammability precautions, and avoidance on open wounds, meninges, or for lumbar puncture.[1][2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ZuraGard.